[go: up one dir, main page]

MX2011007301A - Dabigatran liofilizado. - Google Patents

Dabigatran liofilizado.

Info

Publication number
MX2011007301A
MX2011007301A MX2011007301A MX2011007301A MX2011007301A MX 2011007301 A MX2011007301 A MX 2011007301A MX 2011007301 A MX2011007301 A MX 2011007301A MX 2011007301 A MX2011007301 A MX 2011007301A MX 2011007301 A MX2011007301 A MX 2011007301A
Authority
MX
Mexico
Prior art keywords
dabigatran
lyophilised
assays
lyophilised dabigatran
pharmacodinamic
Prior art date
Application number
MX2011007301A
Other languages
English (en)
Inventor
Joachim Stangier
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40791651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011007301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2011007301A publication Critical patent/MX2011007301A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2430/00—Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/45—Reference solutions for assays of biological material containing protease inhibitors, e.g. sulfonylfluorides, chloromethylketones or organophosphates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención se refiere a una forma liofilizada del dabigatrán de la fórmula I (ver fórmula (I)) su uso como un calibrador en los ensayos para la determinación de los efectos farmacocinéticos del etexilato de dabigatrán, así como para tales ensayos per se. En la preparación de los estándares liofilizados, el dabigatrán se disuelve en una solución ácida acuosa antes del liofilizado.
MX2011007301A 2009-02-02 2010-01-27 Dabigatran liofilizado. MX2011007301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151865 2009-02-02
PCT/EP2010/050925 WO2010086329A1 (en) 2009-02-02 2010-01-27 Lyophilised dabigatran

Publications (1)

Publication Number Publication Date
MX2011007301A true MX2011007301A (es) 2011-08-03

Family

ID=40791651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007301A MX2011007301A (es) 2009-02-02 2010-01-27 Dabigatran liofilizado.

Country Status (16)

Country Link
US (2) US9063163B2 (es)
EP (1) EP2391893B1 (es)
JP (1) JP5611983B2 (es)
KR (1) KR101822368B1 (es)
CN (1) CN102292641A (es)
AU (1) AU2010209804B2 (es)
BR (1) BRPI1007934B1 (es)
CA (1) CA2750976C (es)
DK (1) DK2391893T3 (es)
EA (1) EA020194B1 (es)
ES (1) ES2525251T3 (es)
IL (1) IL213573A (es)
MX (1) MX2011007301A (es)
NZ (1) NZ593787A (es)
PL (1) PL2391893T3 (es)
WO (1) WO2010086329A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2801650B2 (ja) 1989-06-23 1998-09-21 株式会社東芝 空胴結合型進行波管の遅波回路
RU2010143901A (ru) * 2008-03-28 2012-05-10 Бёрингер Ингельхайм Интернациональ Гмбх (De) Способ получения композиций дабигатрана для перорального введения
RU2529798C2 (ru) * 2008-07-14 2014-09-27 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения лекарственных соединений, содержащих дабигатран
JP2013510072A (ja) 2008-11-11 2013-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法
EA201201202A1 (ru) * 2010-03-01 2013-04-30 Рациофарм Гмбх Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
CN102793699B (zh) * 2012-08-06 2014-06-04 严轶东 一种含有达比加群酯的药用组合物
US9176154B2 (en) * 2012-12-12 2015-11-03 Bio-Rad Laboratories, Inc. Calibration process and system
JP6278454B2 (ja) * 2013-03-29 2018-02-14 株式会社Ｌｓｉメディエンス 生体試料中の直接トロンビン阻害薬の測定試薬及び測定方法
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
EP3938741B1 (en) 2019-03-14 2024-05-01 Terumo BCT Biotechnologies, LLC Lyophilization container fill fixture, system and method of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US5858289A (en) * 1997-02-24 1999-01-12 Global Consulting, Inc. Process for preparing compressed shape of ceramic fiber
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
AU7137900A (en) 1999-07-23 2001-02-13 Medical Analysis Systems, Inc. Stabilized coagulation control reagent and method of making same
CN1234363C (zh) * 2003-04-15 2006-01-04 上海医药工业研究院 含有右雷佐生的冻干组合物及其制备方法
US7148067B2 (en) 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005028018A1 (de) * 2005-06-16 2006-12-21 Dade Behring Marburg Gmbh Verfahren zur Standardisierung von Gerinnungstesten
CN1786023A (zh) * 2005-07-27 2006-06-14 西安绿谷制药有限公司 灵芝多糖肽标准品及其制备方法与应用
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR062057A1 (es) * 2006-07-17 2008-10-15 Boehringer Ingelheim Int Uso de los inhibidores directos de la trombina
CN101489549A (zh) * 2006-07-17 2009-07-22 贝林格尔.英格海姆国际有限公司 直接凝血酶抑制剂在心血管领域的新的适应症
CN101313912A (zh) * 2007-05-31 2008-12-03 复旦大学附属中山医院 松果菊苷在制备治疗帕金森病的药物中的应用
CN101105498B (zh) * 2007-08-08 2011-06-01 中国人民解放军军事医学科学院卫生学环境医学研究所 人、大鼠、小鼠hsp70双抗夹心法检测试剂盒
CN101135688A (zh) * 2007-09-27 2008-03-05 宁波美康生物科技有限公司 血清中果糖胺nbt测定方法

Also Published As

Publication number Publication date
PL2391893T3 (pl) 2015-03-31
JP5611983B2 (ja) 2014-10-22
US20120040384A1 (en) 2012-02-16
NZ593787A (en) 2013-09-27
KR101822368B1 (ko) 2018-01-31
US9063163B2 (en) 2015-06-23
BRPI1007934A2 (pt) 2016-02-23
CA2750976C (en) 2018-10-23
JP2012516993A (ja) 2012-07-26
BRPI1007934B1 (pt) 2021-08-31
EA020194B1 (ru) 2014-09-30
CN102292641A (zh) 2011-12-21
KR20110120882A (ko) 2011-11-04
EP2391893A1 (en) 2011-12-07
ES2525251T3 (es) 2014-12-19
US20150240288A1 (en) 2015-08-27
WO2010086329A1 (en) 2010-08-05
IL213573A0 (en) 2011-07-31
IL213573A (en) 2015-05-31
EP2391893B1 (en) 2014-09-03
CA2750976A1 (en) 2010-08-05
AU2010209804A1 (en) 2011-07-07
EA201101152A1 (ru) 2012-03-30
DK2391893T3 (da) 2014-12-01
AU2010209804B2 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
MX2011007301A (es) Dabigatran liofilizado.
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
MX2012005358A (es) Procedimiento para la preparacion de etexilato de dabigatran.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
AU2012213775A8 (en) 7-azaindole derivatives
EA201270216A1 (ru) Фармацевтический состав
CR20130001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
UA111142C2 (uk) Одержання заміщених похідних 2-фторакрилової кислоти
UA118666C2 (uk) Похідні піразолу
EA201270302A1 (ru) Безводные формы производных пиридина
GEP201706623B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
GB2499479A (en) Stabilisation of viral particles
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
EA201171329A1 (ru) Твердый препарат
ECSP11011224A (es) Derivados de tiadiazoles y oxadiazoles, su preparaciòn y su aplicaciòn en terapia
MX349373B (es) Nuevos derivados de pirazina.
UA115357C2 (uk) Похідні піридин-4-ілу
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
EA201270237A1 (ru) Способ получения 1-бензил-3-гидроксиметил-1н-индазола и его производных и необходимые промежуточные соединения, содержащие магний
UA104420C2 (uk) Застосування похідних глутарової кислоти або їх фармацевтично прийнятних солей як протиаритмічних засобів
MX339361B (es) Derivados de alternano.

Legal Events

Date Code Title Description
FG Grant or registration